Dunsire Takes XTuit Helm As First Targets Approach The Clinic
Executive Summary
The privately-held biopharma, focused on fibrotic diseases and cancer, appointed oncology veteran Deborah Dunsire as president and CEO as the firm’s first drug candidates mature toward the clinic.